· Published by Health Canada · Official notice
This is duplicated text of a letter from Genzyme. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 19, 2009
Subject: Preparation and Administration of Thyrogen® (thyrotropin alfa for injection)
Dear Health Care Professional,
Foreign particles have been detected in a small number of vials during the course of routine quality control testing of some products, including Thyrogen, filled at the Genzyme Allston Landing Facility. Genzyme has also received customer reports of foreign particles in some vials of these products. To help ensure that patients are not exposed to foreign particles during product administration, we are writing to alert health care practitioners to the potential presence of such foreign particles and reinforce recommendations for product preparation and administration.
Foreign particles are a known issue in the manufacture of protein products. The particles observed include non-latex rubber originating from the stopper, or stainless steel particles or fiber-like material originating from the manufacturing process. Foreign particles identified by visual inspection prior to administration ranged in size from 140-295 microns (as a comparison, a human hair diameter ranges from 40 to 120 microns). Intramuscular injection of foreign particles of this size may cause local reactions at the site of injection. These include injection site reactions such as pain, local swelling and foreign body granuloma as well as local allergic reactions including rash and urticaria.
To better understand these potential risks to patients, Genzyme has reviewed the Thyrogen global safety database which contains all adverse events reported to Genzyme from January 2004 through 5 Nov 2009 and did not identify any safety concerns that could be potentially related to intramuscular injection of foreign particles.
We are providing the following recommendations for Thyrogen as stated in the Product Monograph:
As stated in the approved product labeling, thyroid hormone withdrawal remains the standard diagnostic modality and therefore is an alternative to Thyrogen, should concern remain.
Please inform your thyroid cancer treatment team of this letter as appropriate. Should you require further information or have any questions, please do not hesitate to contact Genzyme Medical at 800-745-4447 (option 2) or by email at medinfo@genzyme.com.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving Thyrogen® should be reported to Genzyme or Health Canada at the following addresses:
Genzyme
800-2700 Matheson Blvd East
Mississauga Ontario L4W 4V9
Telephone: 1-800-745-4447
Email: medinfo@genzyme.com
Any suspected adverse incident can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701D
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 1-866-234-2345
Fax: 1-866-678-6789
CanadaVigilance@hc-sc.gc.ca
The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Brian Lewis
General Manager